Beaufort Securities reiterated their speculative buy rating on shares of Tiziana Life Sciences PLC (LON:ADI) in a report released on Wednesday morning, StockTargetPrices.com reports.
TRADEMARK VIOLATION NOTICE: This news story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://stocknewstimes.com/2017/08/20/tiziana-life-sciences-plcs-adi-speculative-buy-rating-reiterated-at-beaufort-securities.html.
About Tiziana Life Sciences PLC
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.
Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with MarketBeat.com's FREE daily email newsletter.